Multicenter comparison of genotypic tropism testing: results from viral RNA and proviral DNA

Size: px
Start display at page:

Download "Multicenter comparison of genotypic tropism testing: results from viral RNA and proviral DNA"

Transcription

1 HIV Genotypischer Resistenzalgorithmus Deutschland Multicenter comparison of genotypic tropism testing: results from viral RNA and proviral DNA

2 Financial disclosure Study was financially supported by ViiV Healthcare Germany

3 Aims of the study Genotypic tropism testing from viral RNA is widely accepted as routine diagnostic method. It s usage is implemented by local and European guidelines. Although there is a huge interest in performing tropism testing in patients with low or undetectable viral load, data about tropism testing from proviral DNA ist still limited To better assess the usage of tropism testing from proviral DNA, we conducted a multicenter study to compare V3 loop sequence pairs from viral RNA and proviral DNA in routine diagnostic samples

4 Patrick Braun Lab Dr. Knechten Aachen Martin Däumer Lab Dr. Thiele Kaiserslautern Alexander Thielen MPI Informatik Rolf Kaiser Univ Cologne HIV in Germany The HIV-GRADE laboratory network Labor Lademannbogen HIV-pos. Hamburg ~20% female 2700 Infections/year Lab Fenner 700 deaths/year Hamburg <2% of newborns HIV-pos Martin Obermeier Lab Dr. Berg Berlin Hauke Walter Univ Erlangen Martin Stürmer Univ. Frankfurt Eva Wolf Lab Jäger Munich Ref.: RKI Josef Eberle Univ Munich

5 Specification of the samples Sequencing from viral RNA and proviral DNA was performed in 210 samples Viral load range was between <50 copies/ml and 8.1 million cop./ml HIV1-Subtype was in most cases B (71%)

6 Subtype distribution of samples Subtype was determined using COMET tool (

7 Coreceptor-tropism classification 2 Classification systems were used Geno2pheno [coreceptor] ( Cut-offs for coreceptor tropism classification were used as implemented in the german guidelines FPR <12.5% -> CXCR4 FPR >20% -> CCR5 FPR 12.5% 20% -> equivocal WebPSSM ( Cut-offs as described in: Jensen, M.A. u. a. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol 77, (2003). FPR > > CXCR4 FPR < > CCR5 FPR > equivocal Ambiguous positions in Sequences were resolved with using the highest potential score of any possible sequences

8 Comparison using geno2pheno (N=210) geno2pheno viral CCR5 CXCR4 equivocal proviral CCR CXCR equivocal %

9 Comparison using WebPSSM (N=191) WebPSSM viral CCR5 CXCR4 equivocal proviral CCR CXCR equivocal %

10 Range of FPR values for geno2pheno (all samples N=210) R5

11 Range of FPR values for geno2pheno (divergent samples N=29) R5

12 Range of scores for WebPSSM (all samples N=191) R5

13 Range of scores for WebPSSM (divergent samples N=33) p=0.04 R5

14 Range of scores for WebPSSM (divergent samples N=33) R5 PSSM score viral proviral

15 Conclusions: Genotypic tropism testing from viral RNA and proviral DNA shows a high level of concordance In routine diagnostics tropism testing can be performed from proviral DNA alone and can replace tropism testing from viral RNA to simplify routine diagnostic procedures Genotypic tropism testing from proviral DNA shows at least a trend towards an higher CXCR4 classification If performing genotypic tropism testing from proviral DNA cut-offs should be lowered compared to cut-offs in viral RNA

16 HIV-GRADE association Thomas Berg, Medizinisches Labor Dr. Berg, Berlin Patrick Braun, PZB, Aachen Martin Däumer, Institut für Virologie, Köln Josef Eberle, Pettenkofer-Institut, München Robert Ehret, PZB Aachen Rolf Kaiser, Institut für Virologie, Köln Klaus Korn, NRZ für Retroviren, Erlangen Claudia Kücherer, Robert Koch Institut, Berlin Harm Müller,Labor Fenner, Hamburg Christian Noah, Labor Lademannbogen, Hamburg Martin Stürmer, Institut für Medizinische Virologie, Frankfurt Alexander Thielen, Max Planck Institut Saarbrücken Hauke Walter, NRZ für Retroviren, Erlangen

Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays

Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays Christian Pou 1, Rocío Bellido 1, Francisco M. Codoñer 1, Alexander Thielen 3, Cecilia Cabrera 1, Judith Dalmau

More information

Alexander Thielen 16th European Meeting on HIV & Hepatitis

Alexander Thielen 16th European Meeting on HIV & Hepatitis Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA First Results from the LOWER Study Alexander Thielen, Martin

More information

geno2pheno[ngs-freq]: a novel tool for drug resistance testing in the era of nextgeneration

geno2pheno[ngs-freq]: a novel tool for drug resistance testing in the era of nextgeneration geno2pheno[ngs-freq]: a novel tool for drug resistance testing in the era of nextgeneration sequencing Matthias Döring Max Planck Institute for Informatics AREVIR Meeting 2018 - New Strategies - May 9,

More information

JCM (Revised version, June 23 th 2011)

JCM (Revised version, June 23 th 2011) JCM Accepts, published online ahead of print on 6 July 2011 J. Clin. Microbiol. doi:10.1128/jcm.00908-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation. Elena Knops

Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation. Elena Knops Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation Elena Knops Background - the Berlin patient so far the only person presumed to be cured from HIV by hematopoietic

More information

HIV-GRADE: A Publicly Available, Rules-Based Drug Resistance Interpretation Algorithm Integrating Bioinformatic Knowledge

HIV-GRADE: A Publicly Available, Rules-Based Drug Resistance Interpretation Algorithm Integrating Bioinformatic Knowledge Methods for HIV Resistance Determination and Interpretation Intervirology 2012;55:102 107 DOI: 10.1159/000331999 Published online: January 24, 2012 HIV-GRADE: A Publicly Available, Rules-Based Drug Resistance

More information

AREVIR-GENAFOR-Meeting

AREVIR-GENAFOR-Meeting European Journal of Medical Research Official Organ» Deutsche AIDS-Gesellschaft«VOLUME 12 / SUPPLEMENT III AUGUST 16, 2007 AREVIR-GENAFOR-Meeting April 19-20, 2007, Bonn Abstracts Edited by Mark Oette,

More information

A phylodynamic analysis of HIV-1 in Germany

A phylodynamic analysis of HIV-1 in Germany A phylodynamic analysis of HIV-1 in Germany Prabhav Kalaghatgi Max Planck Institute for Informatics, Saarbrücken RKI workshop 2015, Berlin Number of cases Incidence of HIV-1 in Western Europe Figure 2.

More information

DETECTION OF LOW FREQUENCY CXCR4-USING HIV-1 WITH ULTRA-DEEP PYROSEQUENCING. John Archer. Faculty of Life Sciences University of Manchester

DETECTION OF LOW FREQUENCY CXCR4-USING HIV-1 WITH ULTRA-DEEP PYROSEQUENCING. John Archer. Faculty of Life Sciences University of Manchester DETECTION OF LOW FREQUENCY CXCR4-USING HIV-1 WITH ULTRA-DEEP PYROSEQUENCING John Archer Faculty of Life Sciences University of Manchester HIV Dynamics and Evolution, 2008, Santa Fe, New Mexico. Overview

More information

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09

More information

Journal of Infectious Diseases Advance Access published April 18, Using Ultradeep Pyrosequencing to Study HIV 1 Co receptor Usage in Primary and

Journal of Infectious Diseases Advance Access published April 18, Using Ultradeep Pyrosequencing to Study HIV 1 Co receptor Usage in Primary and Journal of Infectious Diseases Advance Access published April 18, 2013 1 Using Ultradeep Pyrosequencing to Study HIV 1 Co receptor Usage in Primary and Dual Infection Gabriel A. Wagner 1, Mary E. Pacold

More information

Hepatitis C Virus resistance screening and phenotypic NS3-PI-Resistance characterization. Arevir Meeting, 08./09.05.

Hepatitis C Virus resistance screening and phenotypic NS3-PI-Resistance characterization. Arevir Meeting, 08./09.05. Hepatitis C Virus resistance screening and phenotypic NS3-PI-Resistance characterization Arevir Meeting, 08./09.05.2014 Daniel Rupp HCV prevalence 130-170 million patients world wide Ca. 75% of infections

More information

European guidelines on the clinical management of HIV-1 tropism testing

European guidelines on the clinical management of HIV-1 tropism testing European guidelines on the clinical management of HIV-1 tropism testing L P R Vandekerckhove*, A M J Wensing*, R Kaiser, F Brun-Vézinet, B Clotet, A De Luca, S Dressler, F Garcia, A M Geretti, T Klimkait,

More information

HIV-1 resistance testing from proviral DNA

HIV-1 resistance testing from proviral DNA HIV-1 resistance testing from proviral DNA Alexander Thielen AREVIR 2018 Resistance testing from proviral DNA? amount of samples with low viral loads increasing desire to switch under successful therapy

More information

Original Policy Date

Original Policy Date MP 2.04.37 Laboratory Testing for HIV Tropism Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search12:2013 Return to Medical

More information

Laboratory Testing for HIV Tropism. Description

Laboratory Testing for HIV Tropism. Description Section: Medicine Effective Date: July 15, 2015 Subject: Laboratory Testing for HIV Tropism Page: 1 of 19 Last Review Status/Date: June 2015 Laboratory Testing for HIV Tropism Description Human immunodeficiency

More information

Laboratory Testing for HIV Tropism

Laboratory Testing for HIV Tropism Laboratory Testing for HIV Tropism Policy Number: 2.04.49 Last Review: 6/2018 Origination: 6/2015 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for

More information

Laboratory Testing for HIV Tropism

Laboratory Testing for HIV Tropism Laboratory Testing for HIV Tropism Policy Number: 2.04.49 Last Review: 6/2017 Origination: 6/2015 Next Review: 6/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for

More information

Title: Performance of the genotypic algorithms for predicting HIV-1 tropism when. Running head: HIV-1 tropism predictors against enhanced Trofile

Title: Performance of the genotypic algorithms for predicting HIV-1 tropism when. Running head: HIV-1 tropism predictors against enhanced Trofile JCM Accepts, published online ahead of print on 22 September 2010 J. Clin. Microbiol. doi:10.1128/jcm.01204-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Determination of the High Prevalence of Dual/Mixed- or X4- Tropism Among HIV Type 1 CRF01_AE in Hong Kong by Genotyping and Phenotyping Methods

Determination of the High Prevalence of Dual/Mixed- or X4- Tropism Among HIV Type 1 CRF01_AE in Hong Kong by Genotyping and Phenotyping Methods Title Determination of the High Prevalence of Dual/Mixed- or X4- Tropism Among HIV Type 1 CRF01_AE in Hong Kong by Genotyping and Phenotyping Methods Author(s) To, SWC; Chen, JHK; Wong, K; Chan, K; Chen,

More information

Medical Policy Laboratory Testing for HIV Tropism Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory. Description.

Medical Policy Laboratory Testing for HIV Tropism Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory. Description. 2.04.49 Laboratory Testing for HIV Tropism Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date December 31, 2014 Original Policy Date December 31, 2014 Next Review Date December 2015

More information

Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies

Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies BASIC AND TRANSLATIONAL SCIENCE Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies Nico Pfeifer, Dr,* Hauke Walter, MD, and Thomas Lengauer, Dr, PhD* Background:

More information

DNA Genotyping in HIV Infection

DNA Genotyping in HIV Infection Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious

More information

Molecular Surveillance of Recent HIV-Infections in Germany. Priv.-Doz. Dr. Norbert Bannert "HIV und Other Retroviruses" Robert Koch-Institut, Berlin

Molecular Surveillance of Recent HIV-Infections in Germany. Priv.-Doz. Dr. Norbert Bannert HIV und Other Retroviruses Robert Koch-Institut, Berlin Molecular Surveillance of Recent HIV-Infections in Germany Priv.-Doz. Dr. Norbert Bannert "HIV und Other Retroviruses" Robert Koch-Institut, Berlin AREVIR-Meeting, May 9th 2015 Sampling of New HIV Diagnoses

More information

Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism

Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism Meini et al. BMC Infectious Diseases 2013, 13:508 TECHNICAL ADVANCE Open Access Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism Genny Meini 1*, Angelo Materazzi

More information

A Predictive Model for HIV-1 Co-receptor Selectivity

A Predictive Model for HIV-1 Co-receptor Selectivity A Predictive Model for HIV-1 Co-receptor Selectivity Chris A. Kieslich 1, David Shin 1, Aliana López de Victoria 1, Gloria González-Rivera 2, Dimitrios Morikis 1* 1 Department of Bioengineering, University

More information

DRUCK-study Experiences from implementing user survey, rapid testing and risk counselling, involving trained agency staff

DRUCK-study Experiences from implementing user survey, rapid testing and risk counselling, involving trained agency staff DRUCK-study Experiences from implementing user survey, rapid testing and risk counselling, involving trained agency staff Ruth Zimmermann Department for Infectious disease epidemiology HIV, AIDS STI and

More information

Improving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen

Improving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen Improving PI drug resistance scores Jens Verheyen, MD Institute of Virology University Duisburg-Essen Overview Why can all PI drug resistance scores be improved? Do we still need to improve PI drug resistance

More information

Clinical Case. Prof.ssa Cristina Mussini

Clinical Case. Prof.ssa Cristina Mussini Clinical Case Prof.ssa Cristina Mussini Clinical history Male, born in Ivory Coast in 1968. HIV positive since dal 1998 Risk factor: heterosexual contacts He started antiretroviral therapy in 2001 with

More information

Laboratory Testing for HIV Tropism

Laboratory Testing for HIV Tropism Protocol Laboratory Testing for HIV Tropism (20449) Medical Benefit Effective Date: 07/01/15 Next Review Date: 05/18 Preauthorization No Review Dates: 05/09, 03/10, 03/11, 03/12, 03/13, 03/14, 03/15, 05/15,

More information

Professor Jonathan Weber

Professor Jonathan Weber HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust

More information

HIV-1 co-receptor tropism in recently diagnosed patients: correlates of CXCR4-use, impact of subtype and indications for X4/DM virus transmission

HIV-1 co-receptor tropism in recently diagnosed patients: correlates of CXCR4-use, impact of subtype and indications for X4/DM virus transmission Poster nr. O_26 HIV-1 co-receptor tropism in recently diagnosed patients: correlates of CXCR4-use, impact of subtype and indications for X4/DM virus transmission Kristen Chalmet, Kenny Dauwe, Lander Foquet,

More information

Update on HIV-1 Drug Resistance and Tropism Testing

Update on HIV-1 Drug Resistance and Tropism Testing Update on HIV-1 Drug Resistance and Tropism Testing Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and Women s Hospital Harvard Medical School ACTHIV 2011: A State-of-the-Science Conference

More information

Abstract. Introduction

Abstract. Introduction HIV-1 Tropism Determination Using a Phenotypic Env Recombinant Viral Assay Highlights Overestimation of CXCR4-Usage by Genotypic Prediction Algorithms for CRRF01_AE and CRF02_AG Martin Mulinge 1, Morgane

More information

Resistance Workshop. 3rd European HIV Drug

Resistance Workshop. 3rd European HIV Drug 3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance

More information

Correlating HIV tropism with immunological response under combination antiretroviral therapy

Correlating HIV tropism with immunological response under combination antiretroviral therapy DOI: 10.1111/hiv.12365 ORIGINAL RESEARCH Correlating HIV tropism with immunological response under combination antiretroviral therapy J Bader, 1 F Sch oni-affolter, 2 JB oni, 3 M Gorgievski-Hrisoho, 4

More information

Rajesh Kannangai Phone: ; Fax: ; *Corresponding author

Rajesh Kannangai   Phone: ; Fax: ; *Corresponding author Amino acid sequence divergence of Tat protein (exon1) of subtype B and C HIV-1 strains: Does it have implications for vaccine development? Abraham Joseph Kandathil 1, Rajesh Kannangai 1, *, Oriapadickal

More information

New technologies reaching the clinic

New technologies reaching the clinic New technologies reaching the clinic Martin Däumer May 31, 2018 Deep-sequencing Standard Sanger-sequencing...PQIYMDDHTRE... Ultra-deep-sequencing...PQIYMDDHTRE......PQIYMDDHTRE......PQIYVDDHTRE......PQIYMDDHTRE......PQIYMDDHTRE......PQIYMDDHTRE...

More information

48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study

48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study New Microbiologica, 39, 3, 192-196, 2016, ISN 1121-7138 FULL PAPER 48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study

More information

PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients

PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016

More information

Received 31 May 2006/Returned for modification 3 August 2006/Accepted 13 November 2006

Received 31 May 2006/Returned for modification 3 August 2006/Accepted 13 November 2006 JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2007, p. 279 284 Vol. 45, No. 2 0095-1137/07/$08.00 0 doi:10.1128/jcm.01118-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Determining

More information

Purification of viral nucleic acid from serum, plasma, cell-free biological fluids MACHEREY- NAGEL

Purification of viral nucleic acid from serum, plasma, cell-free biological fluids MACHEREY- NAGEL Purification of viral nucleic acid from serum, plasma, cell-free biological fluids Purification of viral nucleic acid from serum, plasma, cell-free biological fluids viral RNA: viral DNA: NucleoSpin RNA

More information

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons

More information

Analysis of HIV-1 Resistance Mutations from various Compartments of the Peripheral Blood in Patients with Low-Level Viremia

Analysis of HIV-1 Resistance Mutations from various Compartments of the Peripheral Blood in Patients with Low-Level Viremia Andrea Freystetter / Christian Paar / Herbert Stekel / Jörg Berg Analysis of HIV-1 Resistance Mutations from various Compartments of the Peripheral Blood in Patients with Low-Level Viremia 107 - Translationale

More information

HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil

HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil 96 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 107(1): 96-101, February 2012 HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil Andre

More information

Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/

Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/ www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:

More information

Low-Level Viremia in HIV

Low-Level Viremia in HIV Mountain West AIDS Education and Training Center Low-Level Viremia in HIV Brian R. Wood, MD Medical Director, Mountain West AETC ECHO Telehealth Program Assistant Professor of Medicine, University of Washington

More information

An Evolutionary Story about HIV

An Evolutionary Story about HIV An Evolutionary Story about HIV Charles Goodnight University of Vermont Based on Freeman and Herron Evolutionary Analysis The Aids Epidemic HIV has infected 60 million people. 1/3 have died so far Worst

More information

HIV/AIDS in Practice. An Expert Commentary with Nelson Michael, MD, PhD. A Clinical Context Report

HIV/AIDS in Practice. An Expert Commentary with Nelson Michael, MD, PhD. A Clinical Context Report HIV/AIDS in Practice An Expert Commentary with Nelson Michael, MD, PhD A Clinical Context Report Clinical Context: HIV/AIDS in Practice Expert Commentary Jointly Sponsored by: and Clinical Context: HIV/AIDS

More information

Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes

Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes 3850 3855 Nucleic Acids Research, 2003, Vol. 31, No. 13 DOI: 10.1093/nar/gkg575 Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes Niko Beerenwinkel*, Martin Däumer 1, Mark Oette 2,

More information

Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope

Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope Evering et al. Retrovirology 2014, 11:65 RESEARCH Open Access Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope Teresa H Evering 1*, Edwin Kamau 2, Leslie

More information

HIV-1 enters host cells by binding to a CD4 receptor and then

HIV-1 enters host cells by binding to a CD4 receptor and then The new england journal of medicine brief report Long-Term Control of HIV by CCR5 Delta32/ Delta32 Stem-Cell Transplantation Gero Hütter, M.D., Daniel Nowak, M.D., Maximilian Mossner, B.S., Susanne Ganepola,

More information

Received 4 August 2005/Accepted 7 December 2005

Received 4 August 2005/Accepted 7 December 2005 JOURNAL OF VIROLOGY, Mar. 2006, p. 2472 2482 Vol. 80, No. 5 0022-538X/06/$08.00 0 doi:10.1128/jvi.80.5.2472 2482.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Extensive Recombination

More information

CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression

CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression Stéphanie Raymond a,b,c, Pierre Delobel a,b,d, Maud Mavigner a, Michelle

More information

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis

More information

Laboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA.

Laboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA. 000000 00000 0000 000 00 0 bdna () 00000 0000 000 00 0 Nuclisens () 000 00 0 000000 00000 0000 000 00 0 Amplicor () Comparison of Amplicor HIV- monitor Test, NucliSens HIV- QT and bdna Versant HIV RNA

More information

Deep-Sequencing of HIV-1

Deep-Sequencing of HIV-1 Deep-Sequencing of HIV-1 The quest for true variants Alexander Thielen, Martin Däumer 09.05.2015 Limitations of drug resistance testing by standard-sequencing Blood plasma RNA extraction RNA Reverse Transcription/

More information

HIV-1 envelope glycoproteins isolated from Viremic non-progressors HIV-infected individuals are fully functional and cytophatic

HIV-1 envelope glycoproteins isolated from Viremic non-progressors HIV-infected individuals are fully functional and cytophatic HIV-1 envelope glycoproteins isolated from Viremic non-progressors HIV-infected individuals are fully functional and cytophatic Silvia Marfil 1, Veronique Hebman 2, Sara Marrero-Hernandez 3, Daniel Márquez-Arce

More information

November/ December 2016

November/ December 2016 November/ December 2016 Corrected version: 02 February 2017 (See Table 3; page 11; program 401) EQA schemes closed Information on sample properties Prof. Dr. Heinz Zeichhardt Dr. Martin Kammel Issued by:

More information

The EuResist GEIE data base

The EuResist GEIE data base Prediction Of Antiretroviral Therapy Outcomes In Poor Resource Countries: Comparison Between Genotype Resistance Testing Based vs. Treatment History Models MCFProsperi 1,MRosen Zvi 2,AAltmann 3,EAharoni

More information

Laboratory diagnostics CH/HIV/0052/17/10/2017

Laboratory diagnostics CH/HIV/0052/17/10/2017 Laboratory diagnostics CH/HIV/0052/17/10/2017 This slide set was created by ViiV Healthcare GmbH with great care in order to provide balanced information about ViiV products and / or application areas.

More information

Estimating Trends in the Proportion of Transmitted and Acquired HIV Drug Resistance in a Long Term Observational Cohort in Germany

Estimating Trends in the Proportion of Transmitted and Acquired HIV Drug Resistance in a Long Term Observational Cohort in Germany Estimating Trends in the Proportion of Transmitted and Acquired HIV Drug Resistance in a Long Term Observational Cohort in Germany Daniel Schmidt 1, Christian Kollan 1, Gerd Fätkenheuer 2, Eugen Schülter

More information

Genotypic Prediction of HIV-1 CRF01-AE Tropism. Faculté de Médecine Toulouse-Purpan, Toulouse, F France 2 ; CHU de

Genotypic Prediction of HIV-1 CRF01-AE Tropism. Faculté de Médecine Toulouse-Purpan, Toulouse, F France 2 ; CHU de JCM Accepts, published online ahead of print on 5 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.02328-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Genotypic Prediction

More information

Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing

Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing 8 The Open Virology Journal, 2008, 2, 8-14 Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing Ina Vandenbroucke *,, Veerle Van Eygen, Evelien

More information

Indication criteria for disease: Myotonic dystrophy type 1 (DM1) [DMPK]

Indication criteria for disease: Myotonic dystrophy type 1 (DM1) [DMPK] deutsche gesellschaft für humangenetik e.v. Indication Criteria for Genetic Testing Evaluation of validity and clinical utility german society of human genetics www.gfhev.de Indication criteria for disease:

More information

Kieran Cashin 1,2, Jasminka Sterjovski 1, Katherine L. Harvey 1,2, Paul A. Ramsland 1,4,5,6, Melissa J. Churchill 1,3,7, Paul R.

Kieran Cashin 1,2, Jasminka Sterjovski 1, Katherine L. Harvey 1,2, Paul A. Ramsland 1,4,5,6, Melissa J. Churchill 1,3,7, Paul R. Covariance of Charged Amino Acids at Positions 322 and 440 of HIV-1 Env Contributes to Coreceptor Specificity of Subtype B Viruses, and Can Be Used to Improve the Performance of V3 Sequence-Based Coreceptor

More information

Complicated viral infections

Complicated viral infections Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western

More information

Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion

Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion R Gupta 1, A Abdulijawad 2, L McCoy 2, D Peppa 3, M Salgado 4, J Martinez- Picado 4, A Wensing

More information

Wenz et al. BMC Public Health (2016) 16:927 DOI /s

Wenz et al. BMC Public Health (2016) 16:927 DOI /s Wenz et al. BMC Public Health (2016) 16:927 DOI 10.1186/s12889-016-3545-4 RESEARCH ARTICLE Open Access High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs:

More information

HIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital

HIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per

More information

Stability of native, lyophilized and inactivated standards

Stability of native, lyophilized and inactivated standards Stability of native, lyophilized and inactivated standards Harry van Drimmelen Bio Quality Control, Heiloo, Netherlands Satellite Meeting before IPFA-PEI 25 th Workshop Twenty-five Years Standardization

More information

High prevalence of CXCR4 usage among treatment-naive CRF01_AE and CRF51_01Binfected HIV-1 subjects in Singapore

High prevalence of CXCR4 usage among treatment-naive CRF01_AE and CRF51_01Binfected HIV-1 subjects in Singapore Ng et al. BMC Infectious Diseases 2013, 13:90 RESEARCH ARTICLE Open Access High prevalence of CXCR4 usage among treatment-naive CRF01_AE and CRF51_01Binfected HIV-1 subjects in Singapore Kah Ying Ng 1,

More information

External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience

External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience Giulio Pisani Biologicals Unit CRIVIB, ISS, Rome SOGAT XXII 14 th 15 th April 2011 - Istituto Superiore di

More information

Innovative diagnostics for HIV, HBV and HCV

Innovative diagnostics for HIV, HBV and HCV Innovative diagnostics for HIV, HBV and HCV Dan Otelea National Institute for Infectious Diseases Bucharest, Romania Disclaimer No conflicts of interest Innovative diagnostics for HIV, HBV and HCV - is

More information

Quantification of HBV, HCV genotype and HIV subtype panels

Quantification of HBV, HCV genotype and HIV subtype panels Quantification of HBV, HCV genotype and HIV subtype panels Harry van Drimmelen 1,2, Wim Quint 2, Nico Lelie 3 and the international NAT study group 1. Biologicals Quality Control, 2. DDL Diagnostic Laboratory,

More information

Disclosure. Relations that could be relevant for the meeting

Disclosure. Relations that could be relevant for the meeting HIV drug resistance A.M.J. Wensing, MD, PhD Senior Consultant Virology, University Medical Center, Utrecht Honorary Professor, University of Witwatersrand, Johannesburg Disclosure Relations that could

More information

IAS 2015 Towards an HIV Cure symposium Vancouver. Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy

IAS 2015 Towards an HIV Cure symposium Vancouver. Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy IAS 25 Towards an HIV Cure symposium Vancouver Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy Questions about long-lived HIV reservoirs Effective ART Memory CD4+ T

More information

Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI

Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI NAT for cellular blood components in Germany Definition of minimal NAT sensitivity limit (ID)

More information

Indication criteria for disease: Spinal muscular atrophy type I-IV [SMN1]

Indication criteria for disease: Spinal muscular atrophy type I-IV [SMN1] deutsche gesellschaft für humangenetik e.v. Indication Criteria for Genetic Testing Evaluation of validity and clinical utility german society of human genetics www.gfhev.de Indication criteria for disease:

More information

Influence of Host Cell Defence during Influenza Vaccine Production in MDCK Cells

Influence of Host Cell Defence during Influenza Vaccine Production in MDCK Cells Vaccine Technology III, 07 June 2010 Puerto Vallarta/Mexico Influence of Host Cell Defence during Influenza Vaccine Production in MDCK Cells T. Frensing 1, C. Seitz 1, B. Heynisch 2 and U. Reichl 1/2 1

More information

17:00 17:45 Meet-the-Professor Immuno-Oncology Fan Yang, Beijing, Christoph Zielinski, Vienna

17:00 17:45 Meet-the-Professor Immuno-Oncology Fan Yang, Beijing, Christoph Zielinski, Vienna 8 th Chinese German Lung Cancer Forum Dresden, Germany, September 8-10, 2016 Precision oncology in lung cancer Thursday, September 8, 2016 17:00 17:45 Meet-the-Professor Immuno-Oncology Fan Yang, Beijing,

More information

Influence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals

Influence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals Influence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals Christoph Boesecke, Hans-Jürgen Stellbrink, Stefan Mauss, Emma Page, Mark Nelson, Sanjay

More information

Trends in molecular diagnostics

Trends in molecular diagnostics Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling

More information

Hepatitis D. Challenges in 2018

Hepatitis D. Challenges in 2018 Hepatitis D Challenges in 2018 Heiner Wedemeyer Essen University Hospital, Germany Germany Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie, Abivax, BMS, Boehringer Ingelheim,

More information

HIV-1 Dual Infection and Neurocognitive Impairment

HIV-1 Dual Infection and Neurocognitive Impairment HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral

More information

HIV/AIDS & Immune Evasion Strategies. The Year First Encounter: Dr. Michael Gottleib. Micro 320: Infectious Disease & Defense

HIV/AIDS & Immune Evasion Strategies. The Year First Encounter: Dr. Michael Gottleib. Micro 320: Infectious Disease & Defense Micro 320: Infectious Disease & Defense HIV/AIDS & Immune Evasion Strategies Wilmore Webley Dept. of Microbiology The Year 1981 Reported by MS Gottlieb, MD, HM Schanker, MD, PT Fan, MD, A Saxon, MD, JD

More information

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.

More information

Quality control of PD-L1 in NSCLC - Results of two German ring trials Dr. Andreas Scheel University Hospital Cologne

Quality control of PD-L1 in NSCLC - Results of two German ring trials Dr. Andreas Scheel University Hospital Cologne Quality control of PD-L1 in NSCLC - Results of two German ring trials 2017-06-07 Dr. Andreas Scheel University Hospital Cologne Step-wise approach Predictive value Biological significance Technical aspects

More information

R Offergeld, D Faensen, S Ritter, O Hamouda Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

R Offergeld, D Faensen, S Ritter, O Hamouda Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany Eurosurveillance, Volume 10, Issue 2, 01 February 2005 Surveillance report HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS C AND HEPATITIS B INFECTIONS AMONG BLOOD DONORS IN GERMANY 2000-2002: RISK OF VIRUS TRANSMISSION

More information

HIV INFECTION: An Overview

HIV INFECTION: An Overview HIV INFECTION: An Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ

More information

Bioinformatics Advance Access published September 6, 2005

Bioinformatics Advance Access published September 6, 2005 BIOINFORMATICS Bioinformatics Advance Access published September 6, 2005 Computational methods for the design of effective therapies against drug resistant HIV strains Niko Beerenwinkel 1,*, Tobias Sing

More information

Received 16 January 2007/Returned for modification 4 March 2007/Accepted 16 April 2007

Received 16 January 2007/Returned for modification 4 March 2007/Accepted 16 April 2007 JOURNAL OF CLINICAL MICROBIOLOGY, June 2007, p. 1838 1842 Vol. 45, No. 6 0095-1137/07/$08.00 0 doi:10.1128/jcm.00113-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Genetic and

More information

Clinical Study Report AI Final 28 Feb Volume: Page:

Clinical Study Report AI Final 28 Feb Volume: Page: Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified

More information

Program. Wednesday, 30 May

Program. Wednesday, 30 May Wednesday, 30 May 9:00 Opening of the meeting 9:15 The role of the human microbiome on HIV infection Roger Paredes, MD, PhD Irsi Caixa Foundation, Barcelona, Spain Session 1 The future of the HIV epidemic

More information

MHH-Biobank (Hannover Unified Biobank = HUB)

MHH-Biobank (Hannover Unified Biobank = HUB) MHH-Biobank (Hannover Unified Biobank = HUB) Prof. Dr. Thomas Illig CEO and scientific head of HUB Working since 01. 01. 2012 in Hannover MHH Klausurtagung, Bad Pyrmont, 09. 02. 2013 Personal Biobanking

More information

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis 1 B R E N D A N M C M U L L A N I N F E C T I O U S D I S E A S E S, S Y D N E Y C H I L D R E N S H O S P I T A L S C H O O L O F W O

More information

Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes

Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2008, p. 887 891 Vol. 46, No. 3 0095-1137/08/$08.00 0 doi:10.1128/jcm.01611-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Evaluation

More information

QUANTITATIVE HIV RNA (VIRAL LOAD)

QUANTITATIVE HIV RNA (VIRAL LOAD) CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: October

More information

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps

More information

CDC site UNAIDS Aids Knowledge Base http://www.cdc.gov/hiv/dhap.htm http://hivinsite.ucsf.edu/insite.jsp?page=kb National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/default.htm

More information